-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

704.O4.3 704. Cellular Immunotherapies: Allogeneic CARs and CARs for T Cell Lymphomas

Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Biological therapies, Workforce, Therapies, Immunotherapy
Monday, December 13, 2021: 10:30 AM-12:00 PM
Sidney Marcus Auditorium, Level 4, Building A (Georgia World Congress Center)
Moderators:
Abdul-Hamid Bazarbachi, MD, EBMT Paris study office / CEREST-TC, Paris, France, Department of Haematology, Saint Antoine Hospital, Paris, France, INSERM UMR 938, Paris, France, Université Pierre et Marie Curie, Paris, France and Razan Mohty, MD, American University of Beirut Medical Center
Disclosures:
No relevant conflicts of interest to declare.
10:30 AM

Lazaros J. Lekakis1*, Frederick L. Locke, MD2, Michael Tees, MD, MPH3, Sattva S. Neelapu, MD4, Shahbaz A. Malik, MD5, Mehdi Hamadani, MD6, Matthew J. Frank, MD, PhD7, Leslie L. Popplewell, MD, FACP8, Jeremy S. Abramson, MD9, Sven de Vos10, Javier Munoz, MD, MS, MBA, FACP11, Chu Ri Shin, MD12*, Arun Balakumaran, MD, PhD12, Lynn Loomis-Navale, MSc12*, Lovely Goyal, PhD12*, Xiangdong Zhou, PhD12* and David B. Miklos, MD, PhD7

1Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL
2Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL
3Colorado Blood Cancer Institute/Sarah Cannon Research Institute, Denver, CO
4Department of Lymphoma and Myeloma, M.D. Anderson Cancer Center, Houston, TX
5Bone Marrow Transplant and Cellular Therapy Program, Sarah Cannon Blood Cancer Center at St. David's South Austin Medical Center, Austin, TX
6BMT & Cellular Therapy Program, Medical College of Wisconsin, Milwaukee, WI
7Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University Hospital, Stanford, CA
8Department of Hematology/HCT, City of Hope National Medical Center, Duarte, CA
9Massachusetts General Hospital Cancer Center, Boston, MA
10University of California-Los Angeles, Los Angeles, CA
11Mayo Clinic, Phoenix, AZ
12Allogene Therapeutics, South San Francisco, CA

10:45 AM

Nitin Jain, MD1, Hagop Kantarjian, MD1, Scott R. Solomon, MD2, Fiona He, MD3, Craig S. Sauter, MD4, Christopher R. Heery, MD5, Alan F. List, MD5, Mark C. Johnson, PhD5*, Yu Lou, MSc5*, Monika Vainorius, MD5*, Koen Van Besien, MD, PhD6, Adam J. Olszewski, MD7, Anthony S. Stein, MD8 and Bijal D. Shah, MD9

1The University of Texas MD Anderson Cancer Center, Houston, TX
2Northside Hospital Cancer Institute, Atlanta, GA
3University of Minnesota, Minneapolis, MN
4Memorial Sloan Kettering Cancer Center, New York, NY
5Precision BioSciences, Inc., Durham, NC
6Presbyterian/Weill Cornell Medical College, New York, NY
7Rhode Island Hospital, Providence, RI
8City of Hope National Medical Center, Duarte, CA
9H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

11:00 AM

Sham Mailankody, MBBS 1, Michaela Liedtke, MD2, Surbhi Sidana, MD3, Jeffrey V. Matous, MD4, Saurabh Chhabra, MD, MS5, Olalekan O. Oluwole, MBBS, MPH6, Shahbaz A. Malik, MD7, Shaji K Kumar, MD8, Rajneesh Nath, MD9, Faiz Anwer, MD10, Jose Carlos Cruz, MD11, Sundar Jagannath12, Myo Htut13, Noopur S. Raje, MD14, David S. Siegel, MD, PhD15, Erin E. Karski, MD16*, Wade Lovelace16*, Afrodite Lourbakos, PhD16*, Srinand Ponnathapura Nandakumar, PhD16*, Arun Balakumaran, MD, PhD16 and Parameswaran Hari5

1Myeloma Service and Cellular Therapeutics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
2Division of Hematology, Department of Medicine, Stanford University, Stanford, CA
3Division of BMT and Cell Therapy, Stanford University Hospital, Stanford, CA
4Colorado Blood Cancer Institute, Denver, CO
5Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI
6Vanderbilt University Medical Center, Nashville, TN
7Bone Marrow Transplant and Cellular Therapy Program, Sarah Cannon Blood Cancer Center at St. David's South Austin Medical Center, Austin, TX
8Mayo Clinic, Rochester, MN
9Banner MD Anderson Cancer Center, Gilbert, AZ
10Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH
11Texas Transplant Institute, San Antonio, TX
12Department of Medicine, Hematology and Medical Oncology, Mount Sinai Medical Center, New York, NY
13Comprehensive Cancer Center, City of Hope National Medical Center, Duarte, CA
14Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA
15John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ
16Allogene Therapeutics, South San Francisco, CA

11:15 AM

Junfang Yang1,2*, Xiao Yang1*, Ying Liu3*, Qinglong Wang3*, Hui Wang, MD1,2*, Jianqiang Li, PhD3 and Peihua Lu, MD1,2,4

1Beijing Lu Daopei Institute of Hematology, Beijing, China
2Hebei Yanda Lu Daopei Hospital, Langfang, China
3Hebei Senlang Biotechnology Co., Ltd., Shijiazhuang, China
4Department of Oncology, Capital Medical University, Beijing, China

11:30 AM

Matthew J. Frigault, MD1, Yi-Bin Chen, MD, MS2, Kathleen M.E. Gallagher, PhD3*, Nora K. Horick, MS4*, Areej El-Jawahri, MD5, Irene Scarfò, PhD6, Marc Wehrli, MD, PhD6*, Lu Huang, PhD6*, Keagan Casey, BS7*, Daniella Cook, BS7*, Thomas Spitzer, MD8*, Steven McAfee, MD8*, Frederic I. Preffer, PhD9*, Myriam Armant, PhD10*, Kit L. Shaw, PhD11*, Heather Daley12*, Sarah Nikiforow, MD, PhD12*, Jerome Ritz, MD13 and Marcela V. Maus, MD7

1HCTCT, Massachusetts General Hospital, Boston, MA
2Bone Marrow Transplant Program, Massachussets General Hospital Cancer Center, Boston, MA
3Massachusetts General Hospital, Harvard Medical School, Charlestown, MA
4Harvard Medical School, Boston, MA
5Blood and Marrow Transplant Program, Massachusetts General Hospital, Allston, MA
6Massachusetts General Hospital, Charlestown, MA
7Cancer Center, Massachusetts General Hospital, Boston, MA
8Massachusetts General Hospital, Boston, MA
9Massachusetts General Hospital Department of Pathology, Boston, MA
10TransLab, Boston Children's Hospital, Boston, MA
11Dana-Farber Cancer Institute, Boston, MA
12Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
13Dana-Farber Cancer Institute, Division of Hematologic Malignancies and Harvard Medical School, Boston, MA

11:45 AM

Rayne H. Rouce, MD1, LaQuisa C. Hill, MD1, Tyler S. Smith2*, Lina Yang, PhD1*, Blakely Boriskie3*, Madhuwanti Srinivasan3*, Huimin Zhang, BS1*, Silvana Perconti, MS1*, Birju Mehta3*, Olga Dakhova, PhD3*, Bambi J. Grilley, RPh1*, Helen E. Heslop, MD, DSc1, Malcolm K. Brenner, MD, PhD1* and Maksim Mamonkin, PhD4

1Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston Methodist Hospital, Houston, TX
2Texas Tech University Health Sciences Center, El Paso, TX
3Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston Methodist Hospital, Houston, TX
4Center for Cell and Gene Therapy, Center For Cell and Gene Therapy, Houston, TX

*signifies non-member of ASH